OBIO Stock Orchestra BioMed Holdings (OBIO, $4.79) price may drop as it broke higher Bollinger Band on Jan 07, 2026
at Tickeron.com
This price move could be a signal that OBIO may fall back below the higher band and head toward the middle band. Traders may consider selling the stock, shorting the stock, or exploring put options. A.I.dvisor backtested 52 similar cases where OBIO's price broke its higher Bollinger Band, and of them led to a successful outcome. Odds of Success:
OBIO in -11.20% downward trend, sliding for three consecutive days on January 30, 2026
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where OBIO declined for three days, in of 222 cases, the price declined further within the following month. The odds of a continued downward trend are .
Technical Analysis (Indicators)
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for OBIO turned negative on January 15, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 50 similar instances when the indicator turned negative. In of the 50 cases the stock turned lower in the days that followed. This puts the odds of success at .
OBIO moved below its 50-day moving average on January 15, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for OBIO crossed bearishly below the 50-day moving average on January 21, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
The Aroon Indicator for OBIO entered a downward trend on January 08, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where OBIO's RSI Indicator exited the oversold zone, of 30 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 61 cases where OBIO's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Momentum Indicator moved above the 0 level on February 03, 2026. You may want to consider a long position or call options on OBIO as a result. In of 100 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where OBIO advanced for three days, in of 213 cases, the price rose further within the following month. The odds of a continued upward trend are .
OBIO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.294) is normal, around the industry mean (27.519). P/E Ratio (0.000) is within average values for comparable stocks, (51.491). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.893). Dividend Yield (0.000) settles around the average of (0.043) among similar stocks. P/S Ratio (60.606) is also within normal values, averaging (331.843).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. OBIO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. OBIO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Advertisement
General Information
Industry Biotechnology